JPRN-UMIN000014840已完成3 期
Phase III trial of the usefulness of new antidepilation conpound, DHL-HisZnNa, against the antineoplastic drug - induced depilation in breast cancer patients - Phase III trial of the usefulness of new antidepilation conpound, DHL-HisZnNa, against the antineoplastic drug - induced depilation in breast cancer patients
Department of Gastroenterological and Pediatric Surgery, Oita University Faculty of Medicine0 个研究点目标入组 100 人开始时间: 2014年8月15日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1)The anamnesis of critical drug hypersensitivity 2)Antineoplastic drug medication is contraindications; The anamnesis of the critical hypersensitivity to the ingredient of anthracycline or the paclitaxel. a)The case which has an anamnesis of hypersensitivity to ingredients, of cosmetics and/or hair restorers b) Cardiac dysfunction or its anamnesis c) Critical myelosuppression d) Critical renal damage e) Critical liver damage f) Infectious disease suspected g) Chicken poxthe case h) Pregnancy or pregnancy is possible. 4) Critical complications (diabetes with poor control, hypertension with poor control, heart failure, renal failure, hepatic failure, etc.)
研究者
相似试验
进行中（未招募）
不适用
Pivotal phase III trial to investigate the efficacy and safety of an Orodispersible Tablet vardenafil versus placebo in the treatment of men with Erectile dysfunction (ED) - a fixed-dose, double-blind, raNdomized multi-center Trial - POTENT I - POTENT IErectile Dysfunction (ED)MedDRA version: 9.1Level: LLTClassification code 10061461Term: Erectile dysfunctionEUCTR2008-000536-40-DEBayer HealthCare AG350
进行中（未招募）
不适用
Pivotal phase III trial to investigate the efficacy and safety of an Orodispersible Tablet vardenafil versus placebo in the treatment of men with Erectile dysfunction (ED) - a fixed-dose, double-blind, raNdomized multi-center Trial - POTENT I - POTENT IErectile Dysfunction (ED)MedDRA version: 9.1Level: LLTClassification code 10061461Term: Erectile dysfunctionEUCTR2008-000536-40-NLBayer HealthCare AG, D-51368 Leverkusen, Germany350
进行中（未招募）
不适用
Pivotal phase III trial to investigate the efficacy and safety of an Orodispersible Tablet vardenafil versus placebo in the treatment of men with Erectile dysfunction (ED) - a fixed-dose, double-blind, raNdomized multi-center Trial - POTENT I - POTENT I * including amendment 1 to ProtocolErectile Dysfunction (ED)MedDRA version: 9.1Level: LLTClassification code 10061461Term: Erectile dysfunctionEUCTR2008-000536-40-BEBayer HealthCare AG, D-51368 Leverkusen, Germany350
进行中（未招募）
1 期
Pivotal phase III trial to investigate the efficacy and safety of an Orodispersible Tablet vardenafil versus placebo in the treatment of men with Erectile dysfunction (ED) - a fixed-dose, double-blind, raNdomized multi-center Trial - POTENT I - POTENT IErectile Dysfunction (ED)MedDRA version: 9.1Level: LLTClassification code 10061461Term: Erectile dysfunctionEUCTR2008-000536-40-FRBayer HealthCare AG, D-51368 Leverkusen, Germany
进行中（未招募）
1 期
A randomised Phase III trial to evaluate the efficacy of chemoimmunotherapy with the monoclonal antibody Campath-1H (Alemtuzumab) given in combination with 2-weekly CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) versus 2-weekly CHOP alone in elderly patients with previously untreated systemic T- cell Lymphoma Short Title: A-CHOP-14 (elderly) - A-CHOP-14 (elderly)Primary therapy of patients with Alk-negative T-NHL in patients aged 61 - 80 yearsICD classification codes : ICD-O 9702/39717/39716/39708/39705/39714/3MedDRA version: 9.1Level: LLTClassification code 10002464Term: Angiomimmunoblastic (AILD, LgX (Kiel Classification)MedDRA version: 9.1Level: LLTClassification code 10025632Term: Malignant lymphomaEUCTR2007-000821-23-BEniversity Medicine Goettingen274